Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Clinical Rheumatology
Literature
1.
Tavakoli H, Rezaii J, Esfandiari K et al (2008) Buerger’s disease: a 10-year experience in Tehran, Iran. Clin Rheumatol (in press)
2.
Saito S, Nishikawa K, Obata H et al (2007) Autologous bone marrow transplantation and hyperbaric oxygen therapy for patients with thromboangiitis obliterans. Angiology 58:429–434PubMedCrossRef
3.
Paraskevas KI, Liapis CD, Briana DD et al (2007) Thromboangiitis obliterans (Buerger's disease): searching for a therapeutic strategy. Angiology 58:75–84PubMedCrossRef
4.
Miyamoto K, Nishigami K, Nagaya N et al (2006) Unblinded pilot study of autologous transplantation of bone marrow mononuclear cells in patients with thromboangiitis obliterans. Circulation 114:2679–2684PubMedCrossRef
5.
Paraskevas KI, Trigka AA, Samara M (2005) Successful intravenous regional sympathetic blockade (Bier's Block) with guanethidine and lidocaine in a patient with advanced Buerger's Disease (thromboangiitis obliterans)—a case report. Angiology 56:493–496PubMedCrossRef
6.
Swigris JJ, Olin JW, Mekhail NA (1999) Implantable spinal cord stimulator to treat the ischemic manifestations of thromboangiitis obliterans (Buerger’s disease). J Vasc Surg 29:928–935PubMedCrossRef
7.
Chander J, Singh L, Lal P et al (2004) Retroperitoneoscopic lumbar sympathectomy for Buerger’s disease: a novel technique. JSLS 8:291–296PubMed
8.
Bozkurt AK, Koksal C, Demirbas, Turkish Buerger’s Disease Research Group et al (2006) A randomized trial of intravenous iloprost (a stable prostacyclin analogue) versus lumbar sympathectomy in the management of Buerger’s disease. Int Angiol 25:162–168PubMed
9.
Ohta T, Ishioashi H, Hosaka M et al (2004) Clinical and social consequences of Buerger disease. J Vasc Surg 39:176–180PubMedCrossRef
Metadata
Title
Treatment-of-choice for Buerger’s disease (thromboangiitis obliterans): still an unresolved issue
Author
Kosmas I. Paraskevas
Publication date
01-04-2008
Publisher
Springer-Verlag
Published in
Clinical Rheumatology / Issue 4/2008
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-008-0843-y

Other articles of this Issue 4/2008

Clinical Rheumatology 4/2008 Go to the issue

Case Report

Oral bisphosphonates in treatment of transient osteoporosis

Original Article

Disease activity in longstanding ankylosing spondylitis—a correlation of clinical and magnetic resonance imaging findings

Case Report

Anti-Ro52 antibodies, antisynthetase antibodies, and antisynthetase syndrome

Case Report

Infliximab can induce a prolonged clinical remission and a decrease in thyroid hormonal requirements in a patient with SAPHO syndrome and hypothyroidism

Letter to the Editor

Return of infliximab efficacy after total knee arthroplasty in a patient with rheumatoid arthritis

Original Article

Change in serum uric acid between baseline and 1-year follow-up and its associated factors in male subjects
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits